Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule. Three groups of patients have received (a) nicotinamide alone, given orally in a dose of 80 mg kg(-1) daily with 5...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group
1997
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223941/ |